Third, numerous pieces of evidence from preclinical studies or clinical trials have indicated that BRD4 may represent a promising therapeutic target for aging-related cardiovascular diseases, such as PAH, HF, and atherosclerosis, as a potent suppressor of inflammatory and fibrotic gene transcription. Here, BRD4 is linked to pulmonary arterial hypertension.